1 March 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Total Voting Rights
In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6), Oncimmune makes the following disclosure with respect to the share capital and voting rights of the Company.
Pursuant to the Company's existing block admission announced on 15 September 2020, and following the exercise of options over 47,647 ordinary shares in aggregate during February 2021 by current and former employees, as at 28 February 2021, the Company's issued share capital was 63,710,093 ordinary shares of £0.01 each with voting rights. The Company does not hold any shares in treasury.
The above figure of 63,710,093 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information:
Oncimmune Holdings plc
Ron Kirschner, Company Secretary
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Chris Lee
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
+44 (0)20 3727 1000